Clinical trial
BAY88-8223, Dose Finding Study in Patients With HRPC
NCT00337155 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00337155 |
|---|---|
| Title | BAY88-8223, Dose Finding Study in Patients With HRPC |
| Official title | A Double Blind, Randomised, Dose Finding, Repeat Dose, Phase II, Multicentre Study of Alpharadin® for the Treatment of Patients With Hormone Refractory Prostate Cancer and Skeletal Metastases |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Radium-223 dichloride (BAY88-8223) |
| Enrollment | 122 |
| Start date | May 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2009 |
| First posted | Jun 15, 2006 |
| Last update posted | Nov 2, 2023 |
| Countries | United Kingdom |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: